Profusa, Inc. Common Stock (PFSA) Stock Score, Valuation & Financial Research

Profusa, Inc. Common Stock is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PFSA

Profusa, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 1.28. These figures are a research snapshot, not a buy or sell recommendation.

What Profusa, Inc. Common Stock does

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Profusa, Inc. is a biotechnology company focused on developing bioengineered sensors designed to detect and transmit clinical-grade data for personal and medical use. The company's business model centers on the research, development, and future commercialization of its proprietary sensor platforms, such as the Lumee Oxygen and Lumee Glucose systems, which are intended to monitor physiological parameters like tissue oxygen levels and glucose concentrations.

Products and services

  • The company develops the Lumee Oxygen Platform for monitoring compromised tissue in peripheral artery disease and chronic wounds, and the Lumee Glucose Platform for interstitial fluid glucose monitoring.

Brands and product families

  • Lumee Oxygen Platform — A platform designed to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. Source
  • Lumee Glucose Platform — A platform designed to monitor glucose levels in interstitial fluid. Source

Business risks and research considerations

  • The company has a history of operating losses and expects to incur significant expenses as it continues to develop and commercialize its products. Source
  • The company's success depends on obtaining and maintaining regulatory approvals for its products in the United States and international markets. Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PFSA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.28
Market capitalization:
1.41M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -42.97M
Free cash flow:
USD -16.26M
Cash:
USD 719K
Total debt:
USD 14M
EPS:
USD -213.25

What stands out

  • Free cash flow is USD -16.26M, negative for the stored period.
  • The balance sheet shows USD 719K of cash versus USD 14M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 13.29M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PFSA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PFSA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is PFSA's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for PFSA to reach sustainable profitability?
  • What does the current share basis reconciled warning mean for the reliability or interpretation of PFSA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PFSA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.